Skip to main content
← SIGNALS
[WORLD]

The Evolution of CRISPR: Companies Targeting the Epigenome for Disease Therapy

As CRISPR technology advances, companies are now exploring epigenome modifications, opening new avenues for treating various diseases.

Editorial StaffJune 26, 20261 MIN READ
The Evolution of CRISPR: Companies Targeting the Epigenome for Disease Therapy

CRISPR technology is undergoing significant evolution, moving beyond traditional gene editing techniques.

A number of companies are now focusing on modifying the epigenome, which could have implications for a wide range of diseases.

This shift in focus highlights the potential of CRISPR to not only edit genes but also to influence gene expression through epigenetic changes.